Top biotech deals in August 2026: steady M&A and continued oncology collaborations

# Overview August 2026 saw fewer headline-making transactions than other months, but notable activity continued across acquisitions, mergers, and collaborations. The month's deals were concentrated in oncology, metabolic and autoimmune disease, and ophthalmology. US companies led dealmaking, followed by firms in the Asia-Pacific region.

# Major acquisitions and mergers Lilly announced the biggest deal: the acquisition of Merida Biosciences for up to $2.875 billion. Merida's technology centers on engineered proteins that target antibodies behind autoimmune and allergic diseases. Its lead program is a fusion protein aimed at Graves' disease and thyroid eye disease.

Jazz Pharmaceuticals acquired Actio Biosciences for $820 million upfront plus up to $500 million in milestones. Actio's lead asset is a small-molecule ion channel inhibitor for epilepsy.

Tarsus Pharmaceuticals purchased Alkeus Pharmaceuticals with $450 million upfront and up to $350 million in milestones. Tarsus acquired a phase 2 small molecule for Stargardt disease, expanding its ophthalmology franchise (Tarsus already markets Xdemvy for demodex blepharitis).

# Big collaborations and platform deals

Genentech also struck another deal in August around a peptide therapy and had earlier collaborations using small-molecule discovery partners.

Pathos AI partnered with Alphamab Biopharmaceuticals over Alphamab's TROP2/HER3 bispecific ADC JSKN016. Alphamab granted Pathos AI rights outside Greater China and received $125 million up front plus up to $2.093 billion in development and commercialization milestones.

# Therapeutic approaches and regional patterns August's deal flow highlighted ADCs, monoclonal antibodies, small molecules, and platform collaborations (e.g., discovery-to-phase-1 ADC partnerships). Oncology and metabolic/autoimmune indications featured prominently.

US companies continued to be the most active acquirers and partners. Asia-Pacific biotechs—particularly China and South Korea—were active as discovery or regional-rights partners.

# Funding and near-term expectations Several of the merged or acquired companies had recently completed private placements to bolster programs ahead of integration or clinical readouts. Regulators' upcoming decisions (for example, the FDA filing tied to dersimelagon) will determine near-term commercial trajectories for some assets.

# Bottom line August 2026 was a month of targeted deals rather than broad consolidation. Strategic buys aimed to fill therapeutic gaps (autoimmune, neurological, ophthalmic), while large platform partnerships continued to concentrate on ADCs and biologic discovery-to-clinic transitions. Expect companies to use small-to-mid-size acquisitions and milestone-based collaborations to manage risk while advancing clinical-stage portfolios.